HALO
Price
$75.85
Change
+$0.80 (+1.07%)
Updated
Jul 15, 04:59 PM (EDT)
Capitalization
8.9B
27 days until earnings call
Intraday BUY SELL Signals
INCY
Price
$115.10
Change
+$0.22 (+0.19%)
Updated
Jul 15, 04:19 PM (EDT)
Capitalization
22.95B
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

HALO vs INCY

HALO vs INCY Comparison Chart in %
View a ticker or compare two or three
VS
HALO vs. INCY commentary
Jul 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HALO is a Hold and INCY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 15, 2026
Stock price -- (HALO: $75.05 vs. INCY: $114.88)
Brand notoriety: HALO: Not notable vs. INCY: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HALO: 49% vs. INCY: 40%
Market capitalization -- HALO: $8.9B vs. INCY: $22.95B
HALO [@Biotechnology] is valued at $8.9B. INCY’s [@Biotechnology] market capitalization is $22.95B. The market cap for tickers in the [@Biotechnology] industry ranges from $120.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HALO’s FA Score shows that 2 FA rating(s) are green whileINCY’s FA Score has 2 green FA rating(s).

  • HALO’s FA Score: 2 green, 3 red.
  • INCY’s FA Score: 2 green, 3 red.
According to our system of comparison, HALO is a better buy in the long-term than INCY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HALO’s TA Score shows that 4 TA indicator(s) are bullish while INCY’s TA Score has 3 bullish TA indicator(s).

  • HALO’s TA Score: 4 bullish, 5 bearish.
  • INCY’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, HALO is a better buy in the short-term than INCY.

Price Growth

HALO (@Biotechnology) experienced а -7.99% price change this week, while INCY (@Biotechnology) price change was -2.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.90%. For the same industry, the average monthly price growth was +7.50%, and the average quarterly price growth was +1978.78%.

Reported Earning Dates

HALO is expected to report earnings on Aug 11, 2026.

INCY is expected to report earnings on Jul 28, 2026.

Industries' Descriptions

@Biotechnology (-2.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INCY($23B) has a higher market cap than HALO($8.9B). HALO has higher P/E ratio than INCY: HALO (26.34) vs INCY (16.23). INCY YTD gains are higher at: 16.311 vs. HALO (11.516). INCY has higher annual earnings (EBITDA): 1.87B vs. HALO (624M). INCY has more cash in the bank: 4.02B vs. HALO (319M). INCY has less debt than HALO: INCY (39.4M) vs HALO (2.15B). INCY has higher revenues than HALO: INCY (5.36B) vs HALO (1.51B).
HALOINCYHALO / INCY
Capitalization8.9B23B39%
EBITDA624M1.87B33%
Gain YTD11.51616.31171%
P/E Ratio26.3416.23162%
Revenue1.51B5.36B28%
Total Cash319M4.02B8%
Total Debt2.15B39.4M5,444%
FUNDAMENTALS RATINGS
HALO vs INCY: Fundamental Ratings
HALO
INCY
OUTLOOK RATING
1..100
2824
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
89
Overvalued
PROFIT vs RISK RATING
1..100
4452
SMR RATING
1..100
1233
PRICE GROWTH RATING
1..100
4314
P/E GROWTH RATING
1..100
12100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HALO's Valuation (83) in the Biotechnology industry is in the same range as INCY (89). This means that HALO’s stock grew similarly to INCY’s over the last 12 months.

HALO's Profit vs Risk Rating (44) in the Biotechnology industry is in the same range as INCY (52). This means that HALO’s stock grew similarly to INCY’s over the last 12 months.

HALO's SMR Rating (12) in the Biotechnology industry is in the same range as INCY (33). This means that HALO’s stock grew similarly to INCY’s over the last 12 months.

INCY's Price Growth Rating (14) in the Biotechnology industry is in the same range as HALO (43). This means that INCY’s stock grew similarly to HALO’s over the last 12 months.

HALO's P/E Growth Rating (12) in the Biotechnology industry is significantly better than the same rating for INCY (100). This means that HALO’s stock grew significantly faster than INCY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HALOINCY
RSI
ODDS (%)
Bearish Trend 2 days ago
62%
Bearish Trend 2 days ago
49%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
59%
Momentum
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
68%
MACD
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
60%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
61%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 20 days ago
80%
Bullish Trend 14 days ago
64%
Declines
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 3 days ago
58%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
65%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
62%
View a ticker or compare two or three
Interact to see
Advertisement
HALO
Daily Signal:
Gain/Loss:
INCY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MRM0.990.05
+4.90%
MEDIROM Healthcare Technologies
LSBK17.00-0.04
-0.23%
Lake Shore Bancorp Inc
FFBC34.23-0.19
-0.55%
First Financial Bancorp
DG120.14-3.30
-2.67%
Dollar General Corp
OFRM17.63-0.81
-4.39%
Once Upon a Farm, PBC

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with HALO. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then HALO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
+0.57%
HALO - INCY
43%
Loosely correlated
-1.39%
AXON - INCY
39%
Loosely correlated
+0.04%
PTCT - INCY
38%
Loosely correlated
-4.02%
RPRX - INCY
38%
Loosely correlated
-1.38%
GMAB - INCY
34%
Loosely correlated
-0.24%
More